Insomnia is the most common sleep disorder among the Quebec population—epidemiological surveys indicate that approximately 30% of adults experience symptoms of insomnia, and that 10 to 15% suffer from clinically significant chronic insomnia, defined as difficulty falling asleep, staying asleep, or waking up too early, occurring at least three nights a week for more than three months, and causing distress or impaired daytime functioning. Despite this high prevalence, insomnia is often undertreated—many people who suffer from it do not discuss it with their doctor, get used to functioning on insufficient sleep, or self-medicate with over-the-counter products whose long-term effectiveness is limited.
Insomnia is not a mere nuisance—it's a medical condition with documented physiological and psychological consequences: impaired cognitive function and concentration, irritability and emotional instability, increased risk of depression and anxiety, elevated blood pressure and cardiovascular risk, disruption of glucose metabolism, weakened immune defenses, and risk of accidents due to daytime sleepiness. The good news is that chronic insomnia is a highly treatable condition—and that the most effective treatments are not sleeping pills, contrary to what many patients suppose, but specific psychotherapeutic approaches whose effectiveness is now solidly established.
Causes of Insomnia: Identifying Medical, Psychological, and Behavioral Factors
Insomnia is rarely monocausal—it most often results from the interaction between predisposing, precipitating, and perpetuating factors, according to the 3P model developed by Arthur Spielman. Predisposing factors are individual characteristics that increase vulnerability to insomnia: physiological hyperactivation of the arousal system, tendency towards anxiety and rumination, family history of sleep disorders. Precipitating factors trigger acute insomnia: stressful event—separation, bereavement, job loss, illness—schedule change, jet lag, acute pain, hospitalization. Perpetuating factors maintain insomnia beyond the triggering event and explain its chronicity: maladaptive behaviors such as staying in bed for a long time without sleeping, compensatory daytime naps, catastrophizing the consequences of sleep deprivation, performance anxiety at bedtime.
Medically, numerous conditions can disrupt sleep and should be investigated when evaluating insomnia: major depression—often manifesting as early awakenings in the latter part of the night—anxiety disorders—with difficulty falling asleep and nocturnal ruminations—chronic pain of any origin—osteoarthritis, low back pain, fibromyalgia—obstructive sleep apnea—fragmenting sleep through repeated micro-awakenings—restless legs syndrome—uncomfortable sensations in the lower limbs forcing movement—hyperthyroidism, heart disease with nocturnal dyspnea, and adverse effects of numerous medications: corticosteroids, beta-blockers, nocturnal diuretics, certain activating antidepressants, decongestants, caffeine, and alcohol. Identifying and treating these underlying causes is often the key to a lasting resolution of insomnia.
Cognitive Behavioral Therapy for Insomnia: The First-Line Treatment
Cognitive Behavioral Therapy for Insomnia (CBT-I) is recognized by all learned societies in sleep medicine as the first-line treatment for chronic insomnia, superior to sleeping pills in the long term and without the side effects associated with medication. CBT-I is a structured program—typically 6 to 8 sessions—that combines several complementary interventions. Sleep restriction is the most powerful but also the most counter-intuitive component: it consists of temporarily limiting the time spent in bed to the estimated actual sleep time, creating a sleep debt that increases sleep pressure and consolidates fragmented sleep into a more compact and efficient period. Stimulus control aims to dissociate the bed from wakefulness and anxiety by reserving the bed for sleep and sexual activities only—leaving the bed if sleep does not occur within 20 minutes.
The cognitive component of CBT-I addresses dysfunctional beliefs and attitudes about sleep that fuel nighttime performance anxiety: the belief that exactly 8 hours of sleep is imperative, catastrophizing the consequences of a poor night's sleep, and attributing all daytime functioning problems to lack of sleep. Sleep psychoeducation—sleep cycles, normal variability, sleep hygiene—complements the approach. CBT-I delivered by a trained psychologist or physician is the optimal modality, but validated digital versions—mobile apps and online programs—have demonstrated significant effectiveness and can be an accessible alternative when a therapist is unavailable or while awaiting treatment. Clinique Omicron physicians can initiate the basic elements of CBT-I, prescribe validated digital resources, and coordinate referrals to sleep psychology when necessary.
Medications for Insomnia: What You Need to Know in 2026
Sleeping pills can play a useful role in managing acute insomnia—for example, during an identified stressful event or to break a cycle of severe insomnia—but their long-term use in chronic insomnia is discouraged by the majority of current clinical practice guidelines. Benzodiazepines—lorazepam, temazepam, nitrazepam—and Z-drugs—zopiclone, zolpidem—are effective in the short term for inducing and maintaining sleep, but their prolonged use is associated with pharmacological tolerance—the need to increase doses for the same effect—physical dependence with withdrawal syndrome upon discontinuation, rebound insomnia, daytime sedation and memory impairment, and a significantly increased risk of falls and fractures in the elderly. Gradual de-prescribing of hypnotic benzodiazepines, when they have been prescribed long-term, is a medical priority—it is ideally carried out in combination with CBT-I.
Extended-release melatonin — Circadin — is approved in Canada for the short-term treatment of insomnia in adults aged 55 and over and has an excellent safety profile with no dependence or withdrawal symptoms. Its effectiveness is modest but real, particularly in improving subjective sleep quality and reducing sleep onset latency. Immediate-release melatonin available over the counter has less robust evidence of effectiveness for chronic insomnia, but may be useful for circadian rhythm disorders such as jet lag and shift work disorder. The new orexin receptor antagonists — suvorexant, lemborexant — represent a more recent therapeutic class with a different mechanism of action from benzodiazepines and a potentially more favorable tolerability profile, but their availability and coverage by drug insurance plans in Quebec remain variable.
Frequently Asked Questions About Insomnia and Medical Consultation
When is it really necessary to see a doctor for insomnia?
A medical consultation is recommended when insomnia lasts for more than four weeks and significantly affects daytime functioning—concentration, mood, work or school performance, interpersonal relationships—or when it is accompanied by symptoms that could indicate an underlying cause—loud snoring and nighttime breathing pauses suggesting sleep apnea, leg restlessness at bedtime, fever, pain, symptoms of depression or anxiety—or when self-medication with over-the-counter products proves insufficient or you feel the need to increase doses, or when insomnia is associated with excessive daytime sleepiness despite sufficient time in bed—this last sign can indicate a primary sleep disorder such as apnea or narcolepsy. A medical consultation helps to distinguish primary insomnia from secondary insomnia, guide towards the most appropriate treatments, and avoid escalation to inappropriate sleeping pills.
Does alcohol help you sleep or worsen insomnia?
Alcohol has an initial sedative effect that makes it easier to fall asleep—which is why many people with insomnia use it as a sleep aid—but its effects on sleep architecture are generally negative. Alcohol suppresses REM sleep in the first half of the night and causes a rebound effect in the second half of the night with more light sleep, micro-arousals, and intense dreams. The result is generally less restorative sleep, with waking often early and difficult despite an apparently normal sleep duration. Alcohol also significantly worsens snoring and sleep apnea by relaxing the muscles of the upper airways. Regular use of alcohol as a sleep aid quickly leads to tolerance—requiring more and more to achieve the same sedative effect—and can contribute to dependence. Limiting alcohol consumption to less than two standard drinks and avoiding any consumption within four hours of bedtime are part of sleep hygiene recommendations.
My child or teen suffers from insomnia — is this common and what should I do?
Sleep disorders in children and adolescents are indeed common but often under-recognized. In preschool and school-aged children, difficulty falling asleep alone, nighttime awakenings, and bedtime resistance are frequent and often linked to behavioral factors – inappropriate sleep associations, irregular schedules, and excessive stimulation in the evening. In adolescents, delayed sleep phase syndrome – a physiological tendency to fall asleep and wake up later due to hormonal changes during puberty – combined with morning school constraints creates chronic structural sleep deprivation. Adolescent insomnia is also frequently associated with anxiety disorders, depression, excessive evening screen use – blue light inhibiting melatonin – and caffeine. Medical consultation is recommended when the sleep problem has lasted for more than a few weeks and affects the child's mood, school performance, or behavior – age-appropriate behavioral approaches are generally very effective.
Omicron Clinic
Need to consult a doctor?
Treatment within 24-48 hours. In-clinic or telemedicine, anywhere in Quebec.
Insurance receipts. 7j/7. No family doctor required.
